$SEEL
Seelos Therapeutics Inc

2012 Q2 Form 10-Q Financial Statement

#000114420412027576 Filed on May 10, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2012 Q1 2011 Q1
Revenue $3.000K $669.0K $1.587M
YoY Change -99.81% -57.84% 9.45%
Cost Of Revenue $83.85K $76.00K $912.4K
YoY Change -90.95% -91.67% -12.26%
Gross Profit $3.000K $669.0K $582.0K
YoY Change -99.49% 14.95% 41.95%
Gross Profit Margin 100.0% 100.0% 36.67%
Selling, General & Admin $3.739M $3.993M $2.906M
YoY Change 1.41% 37.39% 29.74%
% of Gross Profit 124638.07% 596.84% 499.36%
Research & Development $1.033M $1.177M $1.101M
YoY Change -47.61% 6.95% 155.94%
% of Gross Profit 34433.33% 175.93% 189.1%
Depreciation & Amortization $90.00K $98.00K $245.4K
YoY Change -47.06% -60.06% -1.84%
% of Gross Profit 3000.0% 14.65% 42.16%
Operating Expenses $4.350M $4.417M $4.007M
YoY Change -48.33% 10.24% 50.63%
Operating Profit -$4.347M -$3.712M -$3.425M
YoY Change -44.48% 8.39% 52.21%
Interest Expense $168.4K $173.5K $110.9K
YoY Change 97.37% 56.47% -101.59%
% of Operating Profit
Other Income/Expense, Net $25.00K $45.00K $13.74K
YoY Change -30.1% 227.61%
Pretax Income -$4.320M -$3.700M -$3.410M
YoY Change -44.54% 8.5% -63.1%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.926M -$4.713M -$3.411M
YoY Change -36.8% 38.17% -63.08%
Net Earnings / Revenue -164200.0% -704.48% -214.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$54.78M -$58.88M -$56.83M
COMMON SHARES
Basic Shares Outstanding 26.61M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q2 2012 Q1 2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.94M $21.53M $10.18M
YoY Change 96.28% 111.49% 299.22%
Cash & Equivalents $17.94M $21.53M $9.146M
Short-Term Investments
Other Short-Term Assets $920.0K $400.0K $500.0K
YoY Change 411.11% -20.0% 257.14%
Inventory $427.3K $303.1K
Prepaid Expenses
Receivables $460.6K $891.9K $470.0K
Other Receivables $0.00 $0.00 $280.0K
Total Short-Term Assets $19.74M $23.13M $11.42M
YoY Change 110.95% 102.51% 249.24%
LONG-TERM ASSETS
Property, Plant & Equipment $4.227M $4.316M $5.250M
YoY Change -5.23% -17.8% -5.23%
Goodwill $1.130M $1.130M
YoY Change
Intangibles $3.785M $2.844M
YoY Change
Long-Term Investments
YoY Change
Other Assets $311.3K $460.4K $290.0K
YoY Change 19.73% 58.75% -14.71%
Total Long-Term Assets $9.453M $8.750M $8.180M
YoY Change 100.27% 6.97% -56.99%
TOTAL ASSETS
Total Short-Term Assets $19.74M $23.13M $11.42M
Total Long-Term Assets $9.453M $8.750M $8.180M
Total Assets $29.20M $31.88M $19.60M
YoY Change 107.37% 62.64% -12.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $690.0K $740.0K $1.410M
YoY Change -68.78% -47.52%
Accrued Expenses $2.752M $2.462M $680.0K
YoY Change 145.71% 262.09% 385.71%
Deferred Revenue
YoY Change
Short-Term Debt $4.000M $4.000M $220.0K
YoY Change 1718.18% -97.78%
Long-Term Debt Due $0.00 $30.00K
YoY Change -100.0% 0.0%
Total Short-Term Liabilities $10.87M $9.893M $2.540M
YoY Change 195.46% 289.49% -78.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $20.00K $4.100M
YoY Change -100.0% -99.51% -0.24%
Other Long-Term Liabilities $1.480M $97.83K $860.0K
YoY Change 76.19% -88.62% -8.51%
Total Long-Term Liabilities $1.480M $97.83K $4.960M
YoY Change -69.42% -98.03% -1.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.87M $9.893M $2.540M
Total Long-Term Liabilities $1.480M $97.83K $4.960M
Total Liabilities $12.36M $11.70M $7.490M
YoY Change 45.22% 56.23% -56.07%
SHAREHOLDERS EQUITY
Retained Earnings -$229.0M -$224.1M
YoY Change
Common Stock $245.8M $244.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.84M $20.17M $12.11M
YoY Change
Total Liabilities & Shareholders Equity $29.20M $31.88M $19.60M
YoY Change 107.37% 62.64% -12.07%

Cashflow Statement

Concept 2012 Q2 2012 Q1 2011 Q1
OPERATING ACTIVITIES
Net Income -$4.926M -$4.713M -$3.411M
YoY Change -36.8% 38.17% -63.08%
Depreciation, Depletion And Amortization $90.00K $98.00K $245.4K
YoY Change -47.06% -60.06% -1.84%
Cash From Operating Activities -$3.590M -$5.159M -$2.433M
YoY Change 72.6% 112.03% 101.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $20.00K $7.948K
YoY Change -100.0% 151.64% -109.94%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$260.0K $0.00
YoY Change
Cash From Investing Activities $0.00 -$280.0K -$7.948K
YoY Change -100.0% 3423.29% -90.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.49M $2.437M
YoY Change 699.76%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 19.53M 3.471M
YoY Change -100.0% 462.82% -3.86%
NET CHANGE
Cash From Operating Activities -3.590M -5.159M -2.433M
Cash From Investing Activities 0.000 -280.0K -7.948K
Cash From Financing Activities 0.000 19.53M 3.471M
Net Change In Cash -3.590M 14.09M 1.029M
YoY Change 245.19% 1269.16% -55.63%
FREE CASH FLOW
Cash From Operating Activities -$3.590M -$5.159M -$2.433M
Capital Expenditures $0.00 $20.00K $7.948K
Free Cash Flow -$3.590M -$5.179M -$2.441M
YoY Change 87.96% 112.15% 116.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26612169 shares
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10175120
CY2012Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
460367
CY2012Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9893053
CY2012Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
190369
CY2012Q1 us-gaap Business Acquisition Contingent Consideration At Fair Value Current
BusinessAcquisitionContingentConsiderationAtFairValueCurrent
1489128
CY2012Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224070467
CY2012Q1 us-gaap Business Acquisition Contingent Consideration At Fair Value Noncurrent
BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent
527406
CY2012Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2462235
CY2012Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
350928
CY2012Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
51720
CY2012Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
891859
CY2012Q1 us-gaap Assets
Assets
31876615
CY2012Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
790752
CY2012Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
392675
CY2012Q1 us-gaap Common Stock Value
CommonStockValue
26612
CY2012Q1 us-gaap Inventory Net
InventoryNet
303114
CY2012Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
175074
CY2012Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26612169 shares
CY2012Q1 us-gaap Assets Current
AssetsCurrent
23126795
CY2012Q1 us-gaap Goodwill
Goodwill
1129950
CY2012Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
258432
CY2012Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
97826
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21529174
CY2012Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4000000
CY2012Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
737505
CY2012Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31876615
CY2012Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244218758
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
20174903
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26612169 shares
CY2012Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4315503
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2012Q1 us-gaap Liabilities
Liabilities
11701712
CY2012Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2844000
CY2012Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
580310
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9145683
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
280193
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10020683
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10362
CY2011Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value Current
BusinessAcquisitionContingentConsiderationAtFairValueCurrent
1417652
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219357406
CY2011Q4 us-gaap Business Acquisition Contingent Consideration At Fair Value Noncurrent
BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent
499689
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2083588
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
241766
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
51720
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
326926
CY2011Q4 us-gaap Assets
Assets
16615610
CY2011Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
833592
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
395225
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
21348
CY2011Q4 us-gaap Inventory Net
InventoryNet
136149
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
174508
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21347986 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
8191110
CY2011Q4 us-gaap Goodwill
Goodwill
1129950
CY2011Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
258432
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
48241
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7434549
CY2011Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4000000
CY2011Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1137595
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16615610
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
224154238
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
4818180
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21347986 shares
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4384357
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2011Q4 us-gaap Liabilities
Liabilities
11797430
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2630000
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
938546
CY2011Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
35103
CY2011Q1 us-gaap Gross Profit
GrossProfit
582057
CY2011Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7948
CY2011Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13143
CY2011Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
180355
CY2011Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
92559
CY2011Q1 us-gaap Contracts Revenue
ContractsRevenue
1269021
CY2011Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
895447
CY2011Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1598
CY2011Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2433390
CY2011Q1 us-gaap Share Based Compensation
ShareBasedCompensation
619394
CY2011Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-17163
CY2011Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-920
CY2011Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
86652
CY2011Q1 us-gaap Interest Expense
InterestExpense
110887
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-3411006
CY2011Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13736
CY2011Q1 us-gaap Licenses Revenue
LicensesRevenue
202550
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1100546
CY2011Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
245390
CY2011Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
25990
CY2011Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7948
CY2011Q1 us-gaap Sales Revenue Net
SalesRevenueNet
1587065
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3424742
CY2011Q1 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
325083
CY2011Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
535206
CY2011Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
115494
CY2011Q1 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
111480
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2436843
CY2011Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2906253
CY2011Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1029437
CY2011Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31217
CY2011Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
185000
CY2011Q1 us-gaap Interest Paid
InterestPaid
85684
CY2011Q1 us-gaap Operating Expenses
OperatingExpenses
4006799
CY2011Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-203283
CY2011Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16835
CY2011Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3470775
CY2011Q1 us-gaap Cost Of Services
CostOfServices
912449
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2011Q1 apri Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
19141353 shares
CY2012Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q1 dei Trading Symbol
TradingSymbol
APRI
CY2012Q1 dei Entity Registrant Name
EntityRegistrantName
APRICUS BIOSCIENCES, INC.
CY2012Q1 dei Amendment Flag
AmendmentFlag
false
CY2012Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012Q1 dei Document Type
DocumentType
10-Q
CY2012Q1 dei Document Period End Date
DocumentPeriodEndDate
2012-03-31
CY2012Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001017491
CY2012Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
189460
CY2012Q1 us-gaap Gross Profit
GrossProfit
705118
CY2012Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10448
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
51168
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-280031
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3458
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
564933
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
76363
CY2012Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
35371
CY2012Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1017
CY2012Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-42840
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
378647
CY2012Q1 us-gaap Interest Expense
InterestExpense
173501
CY2012Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10448
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-4713061
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-53389
CY2012Q1 us-gaap Licenses Revenue
LicensesRevenue
671044
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5159403
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
534708
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371922
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144171
CY2012Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19489257
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20031
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
781481
CY2012Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
260000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4659672
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-400090
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
110437
CY2012Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5217
CY2012Q1 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
111437
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19489257
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3992868
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14094625
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109162
CY2012Q1 us-gaap Interest Paid
InterestPaid
74307
CY2012Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
166965
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
5364790
CY2012Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-358236
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
177457
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19534059
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2012Q1 apri Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
35371
CY2012Q1 apri Noncash Interest Expense Income Net
NoncashInterestExpenseIncomeNet
99193
CY2012Q1 apri Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
24013386 shares
CY2012Q1 apri Stockholder Rights Plan
StockholderRightsPlan
<div style="font: 10pt Times New Roman, Times, Serif"> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">18.</td> <td>STOCKHOLDER RIGHTS PLAN</td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#xA0;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On March 24, 2011, pursuant to the Company&#x2019;s shareholders rights plan (the &#x201C;Plan&#x201D;) the Company declared a dividend distribution of one preferred share purchase right for each outstanding share of the Company's&#xA0;Common Stock to shareholders of record at the close of business on April 1, 2011.&#xA0; Initially, these rights will not be exercisable and will trade with the shares of the Company's common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &#xA0;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Under the Plan, the rights generally will become exercisable if a person or group acquires beneficial ownership of 15% or more of the Company's common stock in a transaction not approved by the Company's Board. In that situation, each holder of a right (other than the acquiring person) will be entitled to purchase, at the then-current exercise price, additional shares of common stock having a value of twice the exercise price of the right. In addition, if the Company is acquired in a merger or other business combination after an unapproved party acquires more than 15% of the Company's common stock, each holder of the right would then be entitled to purchase at the then-current exercise price, shares of the acquiring company's stock, having a value of twice the exercise price of the right.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &#xA0;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Board may redeem the rights for a nominal amount at any time before an event that causes the rights to become exercisable. The rights will expire on April 1, 2021.</p> </div>

Files In Submission

Name View Source Status
0001144204-12-027576-index-headers.html Edgar Link pending
0001144204-12-027576-index.html Edgar Link pending
0001144204-12-027576.txt Edgar Link pending
0001144204-12-027576-xbrl.zip Edgar Link pending
apri-20120331.xml Edgar Link completed
apri-20120331.xsd Edgar Link pending
apri-20120331_cal.xml Edgar Link unprocessable
apri-20120331_def.xml Edgar Link unprocessable
apri-20120331_lab.xml Edgar Link unprocessable
apri-20120331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v310721_10q.htm Edgar Link pending
v310721_ex31-1.htm Edgar Link pending
v310721_ex31-2.htm Edgar Link pending
v310721_ex32-1.htm Edgar Link pending
v310721_ex32-2.htm Edgar Link pending